Corticosteroids and multiple sclerosis: To treat or not to treat?

Canadian Pharmacists Journal

Volumn 138, Issue 6, 2005, Pages 54-59

  Namaka, Mike ^a   St Laurent, Carol ^b   Vandenbosch, Raelene ^d   Gill, Ranbir ^d   Ruhlen, Dana ^a   Melanson, Maria ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Canadian Armed Forces   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETAMETHASONE; CORTICOSTEROID; CORTISONE; DEXAMETHASONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISONE; TRIAMCINOLONE;

AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DEMYELINATING DISEASE; DEPRESSION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG CLASSIFICATION; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INFECTION; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHARMACIST; PSYCHOSIS; RELAPSE; REMISSION; REVIEW; RISK FACTOR; SLEEP DISORDER; STEROID THERAPY; SYMPTOMATOLOGY; THROMBOEMBOLISM;

EID: 26244462827     PISSN: 17151635     EISSN: None     Source Type: Journal    
DOI: 10.1177/171516350513800601     Document Type: Review

References (30)

1. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993;20(1):17-29.
2. Duquette P, Pleines J, Girard M, et al. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 1992;19(4):466-71.
3. Dipiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy - A Pathophysiologic Approach. 5th ed. Toronto: McGraw-Hill; 2002.
4. Schapiro R. Medications used in the treatment of multiple sclerosis. Phys Med Rehabil Clin N Am 1999 May;10(2):437-46, ix.
5. Rudick RA, Cohen JA, Weinstock-Guttman B, et al. Management of multiple sclerosis. N Engl J Med 1997;337(22):1604-11.
6. Namaka M, Melanson M, Major J, et al. Therapeutic management of multiple sclerosis. Can Pharm J 2001;134(8):31-9.
7. Namaka M, Melanson M. Multiple sclerosis: symptomatic management. Pharmacy Practice 2002;18(2):1-8.
8. Altmann D. Evaluating the evidence for multiple sclerosis as an autoimmune disease. Arch Neurol 2005;62(4):688; author reply 688-9.
9. Reed C. Multiple sclerosis - the treatment options. Hosp Pharm 2003;10:17-21.
10. Calabresi PA, Austin H, Racke MK, et al. Impaired renal function in progressive multiple sclerosis. Neurology 2002;59(11):1799-801.
11. Ozenci V, Kouwenhoven M, Link H. Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. Mult Scler 2002;8:396-404.
12. Van Vollenhoven RF. Corticosteroids in rheumatic disease. Postgrad Med J 1998;103(2):137-42.
13. Pozzilli C, Antonini G, Bagnato, F, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNBI b: a randomized trial in multiple sclerosis. J Neurol 2002;49:50-6.
14. McDonald I. Relapse, remission, and progression in multiple sclerosis. N Engl J Med 2000;343:1486-7.
15. Gayo A, Mozo L, Suarez A, et al. Glucocorticoids increase IL-10 expression in multiple sclerosis acute relapse. J Neuroimmunol 1998;2(85):122-30.
16. U.S. Pharmacist Continuing Education. Therapeutic and adverse effects of glucocorticosteroids. U.S. Pharmacist Prog. No. 430-000-99-028. Available: www.uspharmacist.com/ce/glucocort/lesson.htm (accessed June 10, 2005).
17. Kaufman DI, Trobe JD, Eggenberger ER, et al. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology 2000;54:2039-44.
18. Kupersmith MJ, Kaufman DI, Patty DW. Megadose corticosteroids in multiple sclerosis. Neurology 1994;44:1-4.
19. Tremlett HL, Luscombe DK, Wiles CM. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatr 1998;65:362-5.
20. Tremlett HL, Luscombe DK, Wiles CM. Prescribing for multiple sclerosis patients in general practice: a case-control study. J Clin Pharm Ther 2001;26(6):437-8.
21. Zoorob RJ, Cender D. A different look at corticosteroids. Am Fam Physician 1998;58(2):443-50.
22. National Multiple Sclerosis Society. Corticosteroids. Toronto: MS Society; 2004.
23. Sellebjerg F, Nielsen HS, Frederiksen JL, et al. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999;52:1479-84.
24. Ghosh LM, Kelly SP, Mathews JC, et al. Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England. J Neurol Neurosurg Psychiatr 2002;72:119-21.
25. Sharrack B, Hughes RA, Morris RW, et al. Effects of oral and intravenous methylprednisolone treatment on subsequent multiple sclerosis relapse rate. J Neurol Sci 2000;1(173):73-7.
26. Leussink VI, Merschdorf U, Toyka KV, et al. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001;1(58):91-7.
27. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Neurology 1997;49:1404-13.
28. Goodkin KE, Kinkel RP, Weinstock-Guttman B, et al. A Phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998;51:239-45.
29. Zivadinov R, Rudick R, de Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-47.
30. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000;247:435-42.